Abstracts tagged "Cryoglobulinemia"

Abstract Number: 2039 • 2013 ACR/ARHP Annual Meeting
Micro and Nanoparticles As Possible Causative-Prognostic Co-Factors Of Mixed Cryoglobulinemia Syndrome
Erica Artoni¹, Gian Luca Sighinolfi¹, Daniele Campioli², Marco Sebastiani³, Dilia Giuggioli³ and Clodoveo Ferri⁴, ¹Life Sciences, University of Modena and Reggio Emilia, Modena, Italy, ²Laboratory of Clinical Chemistry, Azienda Ospedaliera - Policlino di Modena, Modena, Italy, ³Internal Medicine, University of Modena and Reggio Emilia, Modena, Italy, ⁴Department of Internal Medicine, University of Modena and Reggio Emilia, Modena, Italy
Background/Purpose: We previously demonstrated that patients affected by membranoproliferative glomerulonephritis and mixed cryoglobulinemia syndrome (MCs) show the presence of circulating micro and nanoparticles (MPs and…
Abstract Number: 1754 • 2013 ACR/ARHP Annual Meeting
Safety and Efficacy Of Peg-IFNa/Ribavirin/Protease Inhibitor Combination In 34 Patients With HCV-Mixed Cryoglobulinemia Vasculitis
David Saadoun¹, Stanislas Pol², Vincent Thibault³, Gilles Pialoux⁴, François Blanc⁵, Lucile Musset⁶, Alexandre Karras⁷, Olivier Decaux⁸, Jean-Marc Ziza⁹, Olivier Lambotte¹⁰ and Patrice Cacoub Sr.¹¹, ¹Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, ²Hepatology, Cochin Hospital, Paris, France, ³Virology, Pitié-Salpétrière, Paris, France, ⁴hôpital Tenon, Paris, France, ⁵hôpital Montpellier, Montpellier, France, ⁶Laboratoire d'immunochimie, Pitié- Salpêtrière, Paris, France, ⁷Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ⁸Department of Internal Medicine, Rennes University Hospital, Rennes, France, ⁹Refferal center for bone and joint infections, Croix Saint Simon Hospital, Paris, France, ¹⁰Internal Medicine, Hopital Kremlin Bicêtre, Kremlin Bicêtre, France, ¹¹Department of Internal Medicine 2., CHU Pitié-Salpêtrière, Paris, France
Background/Purpose: The standard of care treatment of patients presenting a HCV-mixed cryoglobulinemia (MC) vasculitis includes Peg-IFNaplus Ribavirin, w/wo Rituximab. Thirty to 40% of patients are…
Abstract Number: 1657 • 2012 ACR/ARHP Annual Meeting
Peg-IFNa/Ribavirin/Protease Inhibitor Combination Is Highly Effective in HCV-Mixed Cryoglobulinemia Vasculitis
David Saadoun¹, Stanislas Pol², Pascal Lebray Sr.³, François Blanc⁴, Gilles Pialoux⁵, Alexandre Karras⁶, Dorothée Bazin⁷, Emmanuelle Plaisier⁸ and Patrice Cacoub Sr.⁹, ¹DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ²Hepatology, Cochin Hospital, Paris, France, ³Hepatology, Hôpital Pitié Salpétrière, Paris, France, ⁴hôpital Montpellier, Montpellier, France, ⁵hôpital Tenon, Paris, France, ⁶Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ⁷Nouvel Hôpital Civil, Strasbourg, France, ⁸Nephrology, Tenon Hospital, Paris, France, ⁹Department of Internal Medicine 2., CHU Pitié-Salpêtrière, Paris, France
Background/Purpose: The standard of care treatment of patients presenting a HCV-mixed cryoglobulinemia (MC) vasculitis includes Peg-IFNa plus Ribavirin, w/wo Rituximab. Thirty to 40% of patients…
Abstract Number: 1623 • 2012 ACR/ARHP Annual Meeting
Serum Biomarkers Signature Identifies Patients with Overt B-Cell Non-Hodgkin Lymphoma Associated with Mixed Cryoglobulinemia in Chronic HCV Infection
Benjamin Terrier¹, Wahiba Chaara², Guillaume Geri³, David Saadoun⁴, Michelle Rosenzwajg Sr.⁵, Damien Sene Sr.⁶, Adrien Six², David Klatzmann Sr.⁵ and Patrice Cacoub Sr.⁷, ¹Internal Medicine, Cochin University Hospital, Paris, France, ²Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Paris, France, ³Intensive Care Unit, Cochin Hospital, Paris, France, ⁴Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, ⁵Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Paris, France, ⁶Department of Internal Medicine; 5 P3S post-genomic plateform, Groupe Hospitalier Pitié-Salpétrière, Université Pierre et Marie Curie, Paris, France, ⁷Department of Internal Medicine 2., CHU Pitié-Salpêtrière, Paris, France
Background/Purpose: Hepatitis C virus (HCV) is associated with B-cell disorders, including mixed cryoglobulinemia (MC) and B-cell non-Hodgkin lymphoma (B-NHL). Early diagnosis of B-NHL in HCV-infected…
Abstract Number: 1547 • 2012 ACR/ARHP Annual Meeting
A 4 Plus 2 Infusion Protocol of Rituximab Provides Long-Term Beneficial Effects in Patients with HCV-Associated Mixed Cryoglobulinemia with Membranoproliferative Nephritis and Severe Polyneuropathy
Dario Roccatello¹, Savino Sciascia², Simone Baldovino³ and Daniela Rossi¹, ¹Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ²Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, ³Centro di Ricerche di Immunologia Clinica ed Immunopatologia e Documentazione su Malattie Rare (CMID), Università di Torino, Torino, Italy
Background/Purpose: Mixed cryoglobulinemia syndrome (MCs) is a systemic vasculitis characterized by multiple organ involvement due to the vascular deposition of immune-complexes, mainly the cryoglobulins. B…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].